BioSpace News Archive

Eurofins Viracor, a leader in infectious disease and immunology testing, launches EBV inSIGHT™, a functional T Cell test to measure CD4 and CD8 Epstein-Barr virus-specific T cell immune response.

The Biologics & Biosimilars Collective Intelligence Consortium announced that it has received a major grant from the Food & Drug Administration in support of biosimilars research.

Galapagos NV announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company’s Type II variation application for Jyseleca®, a once-daily, oral, JAK1 preferential inhibitor, to amend the European label regarding testicular function after treatment of patients with inflammatory bowel disease and rheumatic conditions.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on October 1, 2022 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in September 2022.

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 1 new employee consisting of an aggregate of 70,000 stock options.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that on September 30, 2022, the Company granted a stock option to purchase 1,200 shares of Karyopharm’s common stock and an award of 800 restricted stock units to one newly-hired employee.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 131,000 shares of the company’s common stock to four new employees.

AIkido Pharma Inc. provided an update on the $3 million share repurchase program authorized by the Company’s Board of Directors on January 21, 2022.

Viewpoint Molecular Targeting, Inc. announced that the U.S. Food and Drug Administration has granted fast track designation for the development of [212Pb]VMT-α-NET for treatment of patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors.

The Pershing Square Sohn Cancer Research Alliance announced the opening of applications for the 2023 Pershing Square Sohn Prize for Young Investigators in Cancer Research.